Fidelitas introduces dispensing and documentation system for methadone treatment in Canada

Fidelitas Medical IT-Solutions, LP announced today the launch of their product DDS, a dispensing and documentation system for methadone treatment. Their mission, according to the company's CEO, Andreas Kunz, is to increase the safety and efficiency of Methadone Maintenance Treatment programs in Canada. "Methadone is useful in the treatment of opiate dependence, but it requires very careful, accurate and transparent handling." Mr. Kunz says that Fidelitas can fulfill these requirements with an automated, tamper proof, documentation and dispensing system that safely manages and records every single mg of methadone – from the time when the methadone arrives at the pharmacy/clinic until the stock is empty. "Pharmacies, clinic owners, authorities, doctors and nurses can be sure to work with a reliable system in which every action is documented safely and accurately." Fidelitas' Vice President, Joakim Jorlander, says, "The fear of making a mistake that could have fatal consequences naturally creates a lot of stress. Our experience from all the fourteen countries we are presently working in tells us that nurses and other staff feel a lot more comfortable doing their job when the documentation and dispensing is interactive and automated."

DDS is listed as a medical device with the U.S. Food and Drug Administration, and the company behind it is registered as a manufacturer of medical devices in both North America (FDA + Health Canada) and Europe. Fidelitas' entry on the North American market has not gone unnoticed. "The high interest is much due to our unique integration of software and dispenser, and it also shows that MMT programs in North America have needs that are yet to be fulfilled," says Fidelitas CEO, Andreas Kunz. "Our mission is to make substitution treatment more safe, more efficient and more transparent. I believe this will make us the best friend of patients, clinics, pharmacies and authorities." Vice President Joakim Jorlander explains that, "this is not just another methadone pump. We are specialists in the complete field of substitution treatment, and this is what makes the DDS stand out. In addition, we are positive that it will save costs for patients, pharmacies, clinics, states, and the government."

DDS is available in Canada through "Healthmark" (www.healthmark.ca). "As one of the leading suppliers of medical and pharmacy products in the country, Healthmark was the natural choice for us when teaming up with a partner in Canada," says Fidelitas CEO Andreas Kunz.